It is made available under a CC-BY-NC-ND 4.0 International license .

1	Multi-site validation of a functional assay to adjudicate SCN5A Brugada							
2	Syndrome-associated variants							
3	Joanne G. Ma, ^{1,2#} Matthew J. O'Neill, ^{3#} Ebony Richardson, ⁴ Kate L. Thomson, ⁵ Jodie Ingles, ⁴							
4	Ayesha Muhammad, ³ Joseph F. Solus, ⁶ Giovanni Davogustto, ⁷ Katherine C. Anderson, ⁷ M.							
5	Benjamin Shoemaker, ⁷ Andrew B. Stergachis, ⁸ Brendan J. Floyd, ⁹ Kyla Dunn, ⁹ Victoria N.							
6	Parikh, ⁹ Henry Chubb, ⁹ Mark J. Perrin, ¹⁰ Dan M. Roden, ¹¹ Jamie I. Vandenberg, ^{1,2*} Chai-Ann							
7	Ng, ^{1,2} * Andrew M. Glazer, ⁶ *							
8								
9	[#] Equally contributed to this work							
10	* Jointly supervised this work							
11								
12	1. Mark Cowley Lidwill Research Program in Cardiac Electrophysiology, Victor Chang							
13	Cardiac Research Institute, Darlinghurst, NSW, Australia.							
14	2. School of Clinical Medicine, UNSW Sydney, Darlinghurst, NSW, Australia.							
15	3. Vanderbilt University School of Medicine, Nashville, TN, USA.							
16	4. Clinical Genomics Laboratory, Centre for Population Genomics, Garvan Institute of							
17	Medical Research, Darlinghurst, NSW, Australia and Murdoch Children Research Institute,							
18	Melbourne, Australia.							
19	5. Oxford Genetics Laboratories, Churchill Hospital, Oxford, UK.							
20	6. Vanderbilt Center for Arrhythmia Research and Therapeutics (VanCART), Division of							
21	Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center,							
22	Nashville, TN, USA.							

medRxiv preprint doi: https://doi.org/10.1101/2023.12.19.23299592; this version posted December 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

23 7. Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University
24 Medical Center, Nashville, TN, USA.

8. University of Washington School of Medicine, Department of Medicine, Seattle, WA, USA.

26 9. Stanford Center for Inherited Cardiovascular Disease, Stanford University School of

27 Medicine, Stanford, CA, USA.

28 10. Department of Genomic Medicine, Royal Melbourne Hospital, Victoria, Australia.

11. Vanderbilt Center for Arrhythmia Research and Therapeutics (VanCART), Departments
of Medicine, Pharmacology, and Biomedical Informatics, Vanderbilt University Medical
Center, Nashville, TN, USA.

32

33 *Correspondence: <u>j.vandenberg@victorchang.edu.au</u> (J.I.V.), <u>c.ng@victorchang.edu.au</u>
34 (C.N), <u>andrew.m.glazer@vumc.org</u> (A.M.G.)

35

36 Abstract

37 Brugada Syndrome (BrS) is an inheritable arrhythmia condition that is associated with rare, 38 loss-of-function variants in the cardiac sodium channel gene, SCN5A. Interpreting the 39 pathogenicity of SCN5A missense variants is challenging and ~79% of SCN5A missense 40 variants in ClinVar are currently classified as Variants of Uncertain Significance (VUS). An in 41 vitro SCN5A-BrS automated patch clamp assay was generated for high-throughput 42 functional studies of Na_V1.5. The assay was independently studied at two separate research 43 sites - Vanderbilt University Medical Center and Victor Chang Cardiac Research Institute -44 revealing strong correlations, including peak I_{Na} density (R^2 =0.86). The assay was calibrated 45 according to ClinGen Sequence Variant Interpretation recommendations using high-46 confidence variant controls (n=49). Normal and abnormal ranges of function were

It is made available under a CC-BY-NC-ND 4.0 International license .

47 established based on the distribution of benign variant assay results. The assay accurately 48 distinguished benign controls (24/25) from pathogenic controls (23/24). Odds of 49 Pathogenicity values derived from the experimental results yielded 0.042 for normal function 50 (BS3 criterion) and 24.0 for abnormal function (PS3 criterion), resulting in up to strong 51 evidence for both ACMG criteria. The calibrated assay was then used to study SCN5A VUS 52 observed in four families with BrS and other arrhythmia phenotypes associated with SCN5A 53 loss-of-function. The assay revealed loss-of-function for three of four variants, enabling 54 reclassification to likely pathogenic. This validated APC assay provides clinical-grade 55 functional evidence for the reclassification of current VUS and will aid future SCN5A-BrS 56 variant classification.

57

58

59 Introduction

60 Brugada Syndrome (BrS) is an autosomal dominant disease characterized by ST-segment elevation in the right precordial leads (V1-V3) of the electrocardiogram (ECG).¹ Patients with 61 62 the definitive ("Type 1") BrS ECG pattern are at increased risk of sudden cardiac death due to ventricular fibrillation.² Sudden cardiac death may be the first disease manifestation, 63 64 making early identification of at-risk patients critical. Up to 30% of BrS patients have rare variants in SCN5A, which encodes Nav1.5, the cardiac voltage-gated sodium channel.³ BrS-65 66 associated SCN5A variants are loss-of-function (LOF) and decrease cardiac excitability and 67 reduce electrical conduction velocity. A ClinGen expert panel asserted that SCN5A is the only gene for which rare variants are definitively associated with BrS.⁴ BrS is also 68 69 substantially influenced by common genetic variation, with 12 common loci identified 70 throughout the genome in a recent genome-wide association study.⁵

It is made available under a CC-BY-NC-ND 4.0 International license .

71 Genetic testing offers the ability to identify individuals at risk for BrS, and proactively 72 optimize medical management before they experience life-threatening cardiac events.^{6,7} 73 However, classification of variants in SCN5A remains challenging as SCN5A variants can 74 have normal function or cause LOF or gain-of-function (GOF). All variants are currently 75 classified by the ACMG/AMP v3 framework as benign (B), likely benign (LB), variant of uncertain significance (VUS), likely pathogenic (LP), or pathogenic (P).⁸ Unfortunately, ~79% 76 of missense SCN5A variants in ClinVar are currently classified as VUS.^{9,10} This high burden 77 of VUS has resulted in underdiagnosis, misdiagnosis, or inappropriate interventions.^{11,12} 78

79 High-throughput functional assays provide an opportunity to improve variant classifications.⁸ 80 Manual patch clamping is the gold-standard method for measuring the function of ion 81 channel variants. However, patch clamping is low-throughput, and individual reports usually 82 describe functional characteristics for one or a small number of variants compared to wild-83 type, precluding assay calibration and generalization across laboratories. High-throughput automated patch-clamp (APC) electrophysiology platforms enable the rapid functional 84 assessment of large numbers of ion channel variants.¹³⁻¹⁷ In the 2015 v3 ACMG/AMP 85 guidelines, well-established functional assay results were applied at a strong level.⁸ These 86 87 criteria are termed BS3 for a normal assay result or PS3 for an abnormal assay result. In 88 2020, the ClinGen Sequence Variant Interpretation (SVI) Working Group recommended 89 instead applying the ACMG/AMP functional assay criteria at a range of evidence strengths depending on the assay's performance on pathogenic and benign variant controls.¹⁸ Jiang et 90 91 al.¹⁶ previously deployed this framework on a APC assay for KCNH2-related Long QT 92 Syndrome, with functional data initially providing moderate-strength evidence for clinical 93 classifications.¹⁶ This KCNH2 assay was recently upgraded to strong evidence strength by 94 including more variant controls.¹⁹ This framework has not yet been applied to any other APC 95 assays, such as an APC assay for Brugada Syndrome (SCN5A-BrS). Furthermore, multi-site replication of APC assay calibration has not yet been reported, an important step in 96 97 promoting reproducibility.

It is made available under a CC-BY-NC-ND 4.0 International license .

In this study, we calibrate an SCN5A-BrS APC assay using a large set of P/LP and B variant controls. We demonstrate high replicability of this assay between two independent research centers and high concordance with clinical classifications. We then used the calibrated assay to provide functional evidence for reclassification of SCN5A VUS identified in clinical cases of BrS and other severe arrhythmias.

103

104

105 Materials and Methods

106 SCN5A transcript

Variants were annotated and experimentally studied using the MANE Select *SCN5A* transcript ENST00000423572.7 (NM_000335.5), the most common transcript in the adult heart.²⁰ This 2015-amino acid transcript includes the adult exon 6A and does not include the alternatively spliced Gln1077 residue. In some previous studies, variants have been annotated according to the 2016-amino acid transcript that includes adult exon 6A and contains Gln1077, ENST00000333535.^{17,21} Table S1 shows variants annotated according to both reference transcripts.

114

115 Classification of SCN5A variants

Variant controls were classified using the 2015 ACMG/AMP v3 criteria for variant interpretation⁸ by a team of clinical geneticists and cardiac genetic counselors. Candidate SCN5A variants were selected from the ClinVar⁹ and gnomAD variant databases (v2.1.1 and v3.1.2).²² For the classification of benign variants, the maximum credible allele frequency of SCN5A variants in population databases was defined using the allele frequency app (http://cardiodb.org/allelefrequencyapp/)²³ with an inputted BrS prevalence of 1 in 2000.²⁴

It is made available under a CC-BY-NC-ND 4.0 International license .

122 allele heterogeneity of 0.02, genetic heterogeneity of 0.3, and penetrance set to the lowest 123 setting of 0.01. Using these thresholds, BA1 can be applied as the stand-alone criteria for all variants meeting a maximum credible population allele frequency of 0.00015.²⁵ However, for 124 125 identifying control benign variants, we conservatively applied BA1 to variants with a 126 maximum credible allele frequency of 0.0003 in gnomAD. P/LP variants for BrS were classified with multiple ACMG/AMP criteria,²⁶ including the number of probands with 127 128 consistent disease phenotype (PS4), absence or rarity of allele in large scale population 129 databases (maximum allele frequency of 3 in 100,000 alleles; PM2_supporting), location of 130 variant (PM1),²⁷ in silico predictors (PP3) including Metascores (MetaLR, MetaSVM, MetaRNN, REVEL²⁸) and VarSome²⁹, and segregation data (PP1). Clinical databases from 131 132 the Centre for Population Genomics and Oxford Genetics Laboratories provided additional 133 proband evidence for pathogenic classifications. The final set of 25 B variant controls is 134 shown in Table S2 and the final set of 24 P/LP variant controls is shown in Table S3.

135

136 SCN5A automated patch clamp assay

137 We followed previously reported protocols to independently generate stable HEK293 variant cell lines (Victor Chang Cardiac Research Institute, VCCRI;^{16,30} Vanderbilt University Medical 138 Center, VUMC).^{17,31} Briefly, SCN5A variant constructs were cloned or subcloned 139 140 independently using a QuikChange Lightning Mutagenesis kit (Agilent) into a 141 AttB:SCN5A:IRES:mCherry-blasticidinR plasmid (VUMC), or into pcDNA[™]5/FRT/TO 142 (Thermo Fisher Scientific) by Genscript Inc. (Piscataway, USA) (VCCRI). See Table S4 for a 143 description of all primers used in this study. Plasmids encoding different variants were 144 transfected into modified HEK293 cell lines at each site. VUMC used a "negative selection" landing pad system (a gift from Kenneth Matreyek and Doug Fowler).³² HEK293 negative 145 146 selection landing pad cells were co-transfected with a AttB-containing SCN5A variant plasmid and a plasmid bearing Bxb1 recombinase (a gift from Pawel Pelczar³³, Addgene 147 148 plasmid #51271) with Lipofectamine 2000 (Thermo Fisher Scientific) following

It is made available under a CC-BY-NC-ND 4.0 International license .

149 manufacturer's instructions. Cells were grown in selection media containing 5 ug/mL 150 doxycycline (to induce promoter expression; Sigma-Aldrich), 100 ug/mL blasticidin S (to 151 eliminate cells not expressing the blasticidin-resistant plasmid; Sigma-Aldrich), and 10 nM 152 AP1903 (to eliminate non-integrated cells expressing a AP1903-inducible caspase gene; 153 MedChemExpress). Cells were grown for 10 days and screened by flow cytometry to confirm 154 expression levels. VCCRI generated stable cell lines by co-transfecting an SCN5A variantexpressing pcDNATM5/FRT/TO plasmid with a pOG44 Flp-Recombinase Expression Vector 155 156 (Thermo Fisher Scientific). The plasmids were transfected with Lipofectamine 3000 (Thermo 157 Fisher Scientific) following manufacturer's instructions. Cell lines were grown in selection 158 media containing 200 ug/mL of Hygromycin (Thermo Fisher Scientific) and 10 ug/mL 159 Blasticidin (InvivoGen) for up to 14 days, and SCN5A expression was induced with 200 160 ng/mL doxycycline (Sigma-Aldrich) 48 hours prior to experimentation. Electrophysiology experiments at both sites were conducted on the SyncroPatch 384 PE (Nanion 161 162 Technologies, Munich, Germany) using Nanion chips containing SCN5A wild-type (WT) and 163 variant control cell lines. Data analysis was performed using site-specific, custom SCN5A 164 analysis scripts in R (VUMC) and Matlab (VCCRI). See Figure 1 for an overview of the 165 methods used in this project. See Supplemental Methods and Figure S1 for detailed 166 electrophysiology protocols and site-specific methods.

167

168 Quality control, sample size, and reproducibility

Both sites implemented common quality control criteria for seal resistance (R_{seal}), capacitance (C_{slow}), series resistance (R_{series}) and residual background current after leak correction. We also performed QC for time to peak as a surrogate for adequate voltageclamp control. Lastly, current amplitude thresholds were applied during analysis of channel gating parameters: steady state activation (SSA), steady state inactivation (SSI), and

It is made available under a CC-BY-NC-ND 4.0 International license .

174 recovery from inactivation (RFI). Specific QC parameters applied at each site are presented

175 in Supplemental Methods.

Power calculations for sample sizes were performed based on cells expressing WT *SCN5A* that passed QC controls. Sample size calculation was performed (see Supplemental Methods) to detect a 25% difference at 90% power, where \Box = 0.05. Tests of normality were implemented with Shapiro-Wilk tests. Non-normal variables were transformed with a square root-transformation, then normalized to the WT mean or individual chips or groups of chips to control for plate-to-plate and batch-to-batch variation, respectively.

182

183 Z-score and OddsPath calculations

For each functional property, normalized means of WT and benign variants were combined to establish thresholds to distinguish variants with normal function from variants with abnormal function. Z-scores were calculated (Equation 1) for all measured values to quantify each variant's function, with smaller Z-scores associated with lower values (such as lower current density).

189
$$Z = \frac{Raw \ value - Mean_{Benign}}{SD_{Benign}}$$
 Equation 1

190 For I_{Na} density, variants with Z-scores between -2 and +2 were considered to have normal 191 function. For I_{Na} density, variants with a Z-score between -2 and -4 were considered 192 moderate LOF and variants with a Z-score below -4 were considered severe LOF ¹⁹. For 193 SSA, SSI, and RFI, variants with Z > 4 or Z < -4 were considered abnormal. The evidence 194 strength for each SCN5A functional property was calculated according to the Odds of 195 Pathogenicity (OddsPath) equations as recommended by the ClinGen Sequence Variant Interpretation working group ^{18,26}. A spreadsheet detailing the OddsPath calculations is 196 197 presented in Table S8.

It is made available under a CC-BY-NC-ND 4.0 International license .

198

199 Analysis of channel functional properties

200 SCN5A functional properties analyzed in this assay were peak sodium current (I_{Na}) density, 201 SSA, SSI and RFI. Diagrams of voltage protocols are presented in Figure S1 and equations 202 for analysis used in this study are presented in the Supplementary Methods. The I_{Na} density 203 was measured at -30 mV following a holding potential of either -120 mV (VUMC and VCCRI) 204 or -90 mV (VCCRI). After quality control, activating current amplitude was divided by cell 205 capacitance to calculate current density normalized to cell size, measured in pA/pF. SSA 206 was obtained by measuring currents in cells depolarized from a holding potential of -120 mV 207 to voltages in the range -100 mV to 0 mV, at 5 mV increments. SSA was fit to the Boltzmann 208 equation using nonlinear least-squares to determine the voltage at which half of the 209 channels were activated (SSA V_{50}). SSI was determined after holding channels at voltages 210 in the range -140 mV to -40 mV for 500 ms (in 5 mV increments) then measuring tail current 211 amplitudes recorded at -30 mV. These values were fit to the Boltzmann equation to 212 determine SSI V_{50} . RFI was determined by the ratio of current amplitude at a test pulse to 213 current amplitude at a pre-pulse with increasing time intervals between the two pulses. The 214 time at which channels were half recovered (T_{50}) was used for analysis.

215

216 Clinical evaluation and genetic testing

217 *SCN5A* VUS were identified in patients with BrS diagnoses or severe cardiac conduction 218 disease from four tertiary care centers: Vanderbilt University Medical Center, Stanford 219 Medicine, University of Washington Hospital, and The Royal Melbourne Hospital. All studies 220 were approved by local Institutional Review Boards/Research Ethics Committees and 221 informed consent was obtained as required by these entities. Clinical information was 222 obtained through retrospective review of medical records. Patients underwent commercial

It is made available under a CC-BY-NC-ND 4.0 International license .

223 genetic testing using gene-panels. Functional characterization of each clinical SCN5A VUS 224 using the calibrated assay was performed as described above. Although the APC OddsPath 225 calculations supported the use of BS3 strong, we conservatively applied a graded evidence 226 strength scheme. Z-scores of the square root transformed current density values were used 227 to calculate the appropriate ACMG criterion (PS3_strong for Z < -4, PS3_moderate for -4 < Z 228 < -3, PS3_supporting for -3 < Z < -2, BS3_supporting for -2 < Z < -1, and BS3_moderate for 229 Z > -1). We note that we conservatively applied BS3 moderate evidence strength for 230 variants with -1 < Z < 1 and BS3_supporting for -2 < Z < -1 and Z > 1. This was due to 231 caution over misclassifying a disease-causing variant as benign or likely benign, and 232 because we have not yet calibrated the assay to detect other types of SCN5A dysfunction 233 such as GOF. Variant reclassification was independently performed at each clinical site by a 234 genetic counselor, clinical geneticist, or physician specializing in genomic medicine.

235

236

237 Results

238 Square root transformation, power calculation

239 We measured typical I_{Na} currents from 2,727 cells expressing WT SCN5A (Figure 2A-B). 240 The raw current densities showed a non-Gaussian distribution (Figure 2C-D, p<0.0001, 241 Shapiro-Wilk test). The current density values were converted to a more normal distribution 242 by application of a square-root transformation (Figure 2E-F; p=0.304 and p<0.0001 at VCCRI and VUMC, respectively; Shapiro-Wilk test).^{16,34} Using a sample size power 243 244 calculation (see Supplemental Equations), we determined that a minimum of 30 cells per 245 variant was required to detect a 25% difference in current density at 90% power with a 95% 246 confidence interval. We therefore measured at least 30 cells per site for each variant with 247 replicates spanning independent transfections, chips, and experimental days.

It is made available under a CC-BY-NC-ND 4.0 International license .

248

249 Peak I_{Na} density distinguishes benign from pathogenic variants

250 Many BrS-associated SCN5A variants have reductions in peak I_{Na} density, the maximum amount of current through the channel.²¹ Z-scores were calculated using the distribution of 251 252 25 benign variant controls as reference. Z-scores between -2 and 2 were considered normal, 253 and Z-scores between -2 and -4 were considered moderate LOF, and Z-scores smaller than 254 -4 were considered severe LOF. Normalized current densities for B and P/LP variant 255 controls are shown for VCCRI (Figure 3A) and VUMC (Figure 3B), and the combined VCCRI 256 and VUMC dataset (Figure 3C). Variant-level data are summarized in Tables S5-S7. Across 257 the 49 variants, we observed excellent correlation between sites for peak $I_{\rm Na}$ density despite slight differences in cell systems, protocols, and analysis pipelines (Figure 3D; R² = 0.86). 258 259 Overall, 25/25 B and 23/24 P/LP variant controls had matching results between the two sites 260 for peak $I_{\rm Na}$ density, considering this variable as a binary outcome of normal or abnormal. 261 The only variant discordant between the two sites was p.Arg1631His, an LP variant that had 262 reduced I_{Na} density in the VCCRI dataset and normal function in the VUMC dataset (Figure 263 3).

264 We observed a strong predictive ability of peak I_{Na} current to distinguish benign from 265 pathogenic variant controls. In the merged dataset (Figure 3C), 22 of 24 P/LP variant 266 controls had moderate or severe LOF (Z < -2). Two P/LP variant controls had current density 267 within normal ranges: p.Arg1643Cys (Z = -0.71) and p.Arg1631His (Z = -1.6), though VCCRI 268 observed partial LOF for p.Arg1631His (Figure 3A). As we describe below, both sites 269 measured abnormal gating properties for p.Arg1631His. In the merged dataset (Figure 3C), 270 24 of 25 B variant controls were within the normal range of function (Z > -2). One benign 271 variant, p.Ser216Leu, had moderate LOF at both sites and a final Z-score of -3.39. Overall, 272 peak I_{Na} density was concordant with ACMG/AMP classifications for 46/49 variants (93.9%).

273

It is made available under a CC-BY-NC-ND 4.0 International license .

274 Incorporation of additional channel gating parameters

275 We next studied variant effects on three additional channel gating parameters: steady state 276 activation (SSA), steady-state inactivation (SSI), and recovery from inactivation (RFI) (Figure 277 4, Supplementary Table 5-7). These parameters quantify the voltages at which channels 278 activate and inactivate and the time needed to recover from inactivation. We observed good 279 to excellent correlation between VCCRI and VUMC for these parameters (SSA R²=0.44; SSI 280 R^2 =0.48; RFI T₅₀ R^2 =0.91; Figure S2-4). Unlike peak I_{Na} density (Figure 3), none of the three 281 gating parameters strongly distinguished B from P/LP controls (Figure 4). We also note that 282 for most variants with LOF – including most P/LP variant controls – these gating parameters 283 could not be measured due to the small I_{Na}. Therefore, we applied a more conservative Z-284 score threshold of ±4 for altered effects. Using this cutoff, five P/LP variants (p.Glu1224Lys, 285 p.Ala735Val, p.Glu1783Lys, p.Arg1631His, and p.Arg1631Cys) and no B variants showed 286 altered gating parameters (Table 1, Figure 4). In particular, two variants had extreme 287 changes in RFI ΔT_{50} : p.Arg1631Cys (Z = 72.74) and p.Arg1631His (Z = 106.09; Figure 4E-F, 288 H-I, Table 1). This finding resolves the initial discordance between the LP classification for 289 p.Arg1631His and the normal-range peak I_{Na} density measured at VUMC. Thus, an 290 integrated analysis of peak current density and other gating parameters yields 23/24 B and 291 24/25 P/LP variants that have concordant functional assay results and clinical classifications. 292

293 Peak I_{Na} density for depolarization from a -90 mV holding potential

Peak I_{Na} density is commonly measured from a holding potential of -120 mV, which ensures that nearly all channels begin the measurement from the closed state. However, under physiological conditions, the resting cardiomyocyte membrane potential is closer to -90 mV.³⁵ We hypothesized that variants with abnormal gating properties such as hyperpolarized SSI may have reduced current density when measured from a holding potential of -90mV (Figure 5A). To test this hypothesis, at VCCRI, peak I_{Na} densities were measured from a

It is made available under a CC-BY-NC-ND 4.0 International license .

300 holding potential of -90 mV (Figure 5). Peak I_{Na} densities measured from holding potentials 301 of -90 mV and -120 mV were highly correlated (R²=0.95, Figure 5B). However, three variants 302 (p.Arg1631Cys, p.Arg1631His and p.Glu1783Lys) had lower I_{Na} density when measured 303 from a holding potential of -90 mV compared to -120 mV (Figure 5B). All three of these 304 variants also had hyperpolarized SSI (Figure 4D, Table 1). We next performed square root transformations of the -90 mV peak $I_{\rm Na}$ density measurements, and used the mean and 305 306 standard deviation of benign variant controls to define Z-scores. This single parameter (peak 307 I_{Na} density measured from a holding potential of -90 mV) yielded 25/25 B and 23/24 P/LP 308 variant controls that have concordant functional assay results and clinical classifications 309 (Figure 5C). In particular, the measurement at -90 mV peak improved the concordance of 310 the B variant p.Ser216Leu (Z = -3.39 at a holding potential of -120 mV, Z = -1.72 at -90 mV) whilst also increasing the B variant p.Glu446Lys (Z = 1.65 at a holding potential of -120 mV, 311 312 Z = 2.37 at -90 mV). Evaluation of p.Glu446Lys gating parameters measured in this study 313 does not suggest altered function (Table S5-7). However, as this SCN5A-BrS assay is only 314 validated against LOF, a calibrated GOF assay may be valuable to explore this variant 315 further.

316

317 Establishment of evidence strength for functional data

Recommendations by the ClinGen SVI working group¹⁸ were applied to evaluate the 318 319 strength of our two SCN5A-BrS assay implementations (Figure 6; Table S8). For our first 320 implementation which combined -120 mV holding potential measurements and gating 321 properties, we observed 24/25 concordant B variants and 23/24 concordant P/LP variants 322 (Figure 6A). This yielded OddsPath scores of 24.0 for pathogenic evidence, and 0.043 for 323 benign evidence (Figure 6B). For our second implementation which considered the single 324 parameter of peak I_{Na} density from a holding potential of -90 mV, we observed 25/25 325 concordant B variants and 23/24 concordant P/LP variants. (Figure 6C). This yielded

It is made available under a CC-BY-NC-ND 4.0 International license .

OddsPath scores of 24.0 for pathogenic evidence, and 0.042 for benign evidence. (Figure 6D). In both cases, these values correspond to application of up to PS3_strong (abnormal function) and BS3_strong (normal function) criteria in the ACMG/AMP classification scheme.⁸

330

331 Functional investigation of clinical SCN5A VUS

The calibrated APC assay was used to assess the function of *SCN5A* VUS identified in patients with a clinical diagnosis of BrS or other severe arrhythmia phenotypes associated with *SCN5A* LOF variants.³⁶ A list of genes tested for each proband is available in Table S9, additional detected non-*SCN5A* variants are available in Table S10, and classification criteria are available in Table S11. Limited pedigrees with clinical annotations are shown in Figure 7, with the sexes of family members anonymized.

338 Family 1. The proband was resuscitated from a ventricular fibrillation cardiac arrest during 339 their teenage years. Cardiac workup led to a diagnosis of Brugada Syndrome and 340 Progressive Cardiac Conduction Defect. Genetic testing identified an in-frame insertion in 341 SCN5A, p.Asn1378 Lys1379insValPhe (c.4133 4134insTGTGTT), which was classified as 342 VUS. APC revealed that the variant was LOF (Z = -7.62), enabling reclassification to LP after 343 application of PS3_strong (Figure 7). Cascade screening revealed that the SCN5A variant 344 was inherited. The proband's affected parent had a history of a seizure disorder and was 345 subsequently found to have cardiac conduction disease. The parent with the SCN5A variant 346 had a history of a seizure disorder and was subsequently found to have cardiac conduction 347 disease. Additionally, two of the probands' grandparents (one on each side of the family) had 348 died suddenly in their 30s or 40s.

Family 2. The proband was a woman in her 40s who presented after an episode of syncope.
Workup revealed fever-induced Type 1 (*i.e.*, definite) Brugada ECG pattern. Genetic testing
uncovered the in-frame deletion p.Phe1751del (c.5251_5253del), which was classified as

It is made available under a CC-BY-NC-ND 4.0 International license .

352 VUS. APC revealed that the variant was LOF (Z = -7.44), enabling reclassification to likely 353 pathogenic after application of PS3_strong. The proband had a family history of recurrent 354 syncope, seizures, and one cardiac arrest. However, besides the proband, the family was 355 hesitant to undergo genetic evaluation, precluding segregation analysis.

Family 3. The proband developed complete heart block at a young age and had a 13 second pause, and received an implanted cardioverter defibrillator (ICD). He developed ventricular tachycardia, received shocks from his ICD, and developed heart failure as an adult. Genetic testing identified an *SCN5A* VUS p.Asn932Lys (c.2796T>G). APC revealed that the variant was LOF (Z = -6.52), enabling reclassification to LP after application of PS3_strong. Cascade screening identified the proband's two young children as variant carriers, and both had a prolonged PR interval (202 msec and 172 msec).

363 Family 4. The proband was a woman in her 60s with an incidental finding of BrS Type 1 364 ECG and rate-related left bundle branch block during exercise testing. She had no history of 365 syncope and there was no family history of sudden cardiac death. Genetic testing identified 366 an SCN5A variant p.Arg1305Cys (c.3913C>T), which has an allele count of 12 in gnomAD 367 v4, and was classified as a VUS. Using APC, we assessed the variant to have normal 368 function (Z = -0.33) and concluded that in this case the SCN5A variant was likely not the 369 cause of the BrS ECG pattern. This variant remained classified as VUS by the clinical testing 370 laboratory after incorporation of the functional data (BS3 moderate).

371

372 Reanalysis of previously published APC data

373 Lastly, we reanalyzed all previously published *SCN5A* APC assay results from our 374 group^{17,31,37} (Table S12). This reanalysis used the same analysis protocol described in this 375 paper, including features like square root transformation of current densities and Z-score-376 derived cutoffs that were not implemented in our previous studies. We also assigned

It is made available under a CC-BY-NC-ND 4.0 International license .

377 recommended functional evidence BS3/PS3 strengths to these variants using our updated

analysis framework (Table S12).

379

380

381 Discussion

This study describes an *SCN5A* functional assay that was independently tested and calibrated by two research centers to facilitate *SCN5A*-BrS variant classification. Significant benefits of this assay include replicability across sites, the ability to distinguish B and P/LP variant controls following ClinGen guidelines, and implementation of Z-scores to quantitatively interpret VUS. We also demonstrate a single parameter (peak current measured from a physiological holding potential of -90 mV) that can accurately distinguish B from P/LP controls.

389

390 Multi-site validation of a SCN5A-BrS patch-clamp assay

391 Independent data generation and analyses were performed at two independent sites with 392 similar experimental and analysis pipelines. To determine the reproducibility of the SCN5A 393 APC assay, each site independently tested all variant controls. Between the two sites, we observed strong correlations for peak current density ($R^2 = 0.86$) and good to excellent 394 395 correlation for the other gating parameters. For peak I_{Na} density, 48/49 variants had 396 concordant results between the two sites (considering each variant as having normal or 397 abnormal function). Future functional assays may benefit from testing at independent sites to 398 demonstrate reproducibility prior to clinical use.

399

It is made available under a CC-BY-NC-ND 4.0 International license .

400 The calibrated assay can discriminate between variant controls

We describe two implementations of the assay, one that integrates peak l_{Na} density and gating measurements, and a second that uses a single parameter (peak l_{Na} density measured from a physiological holding potential). Both implementations yielded concordant results in nearly all variant controls (24/25 B and 23/24 P/LP for implementation 1, 25/25 B and 23/24 for implementation 2). After OddsPath calculations as recommended by the ClinGen SVI working group,¹⁸ both implementations of the assay attained strong levels of evidence for both PS3 (abnormal function) and BS3 (normal function).⁸

408 Two variant controls had discordant results with their clinical classifications in the peak $I_{\rm Na}$ 409 and gating assay, p.Ser216Leu and p.Arg1643Cys. The B variant p.Ser216Leu had partial 410 LOF in peak I_{Na} (Z = -3.39 with holding at -120 mV). In the -90 mV holding potential 411 measurement, the Z-score was increased to Z = -1.72 and fell within the normal-function 412 range (Z within ± 2). A previous report also measured partial LOF for this variant in HEK293 413 cells.³⁸ In addition, this variant has also been reported to have late current in HEK293 cells.³⁹ 414 p.Ser216Leu is present in the population at a much higher than expected frequency for a 415 highly penetrant disease-associated variant (allele frequency > 0.05% in gnomAD).40 416 However, p.Ser216Leu has also been observed in multiple patients with arrhythmia phenotypes, including BrS,^{38,41,42} Type 3 Long QT syndrome,^{43,44} Sudden Infant Death 417 Syndrome,^{39,45,46} and atrial fibrillation.^{47,48} Given the multiple arrhythmia reports and the 418 419 borderline partial LOF phenotype of the variant, p.Ser216Leu may be a risk allele for arrhythmia phenotypes, analogous to *KCNE1* p.Asp85Asn.⁴⁹ The LP variant p.Arg1643Cys 420 421 also had a discordant outcome in our assay, with a functionally normal range peak current (Z 422 = -0.71 and Z = -0.88 with holding potentials of -120 mV and -90 mV, respectively). The only 423 aberrant functional phenotype was a depolarized shift in SSA (+4.31 mV, Z = 3.15), consistent with previous findings.⁵⁰ p.Arg1643Cvs has been previously reported in multiple 424 BrS cases⁵⁰⁻⁵³ and we classified it as LP (PS4_moderate, PM5, PM2_supporting, PP3). 425 426 Although p.Arg1643Cys was absent from gnomAD v2.1.1 and v3.1.2 used in this study, it is

It is made available under a CC-BY-NC-ND 4.0 International license .

427 present in gnomAD v4 (allele count of 4/86,258 alleles in the South Asian population). Future 428 work could further investigate the functional impact of p.Ser216Leu and p.Arg1643Cys on 429 channel function in other contexts and cell models (e.g. cardiomyocytes) and help further 430 clarify their disease risk.

431

432 Incorporation of gating changes as well as current density measurements

433 Peak current is the strongest molecular correlate of BrS and has been associated with risk of 434 events and disease penetrance.^{21,54} Most patch clamp studies of SCN5A have used a 435 resting membrane potential of -120 mV in activation protocols to ensure that nearly all 436 channels were closed at the start of the measurement. However, this configuration might 437 overestimate the available peak I_{Na} for BrS-associated SCN5A variants that affect Na_V1.5 438 gating. Some studies have also evaluated the impact of using a resting potential of -90 mV. which is similar to the resting potential of human cardiomyocytes.⁵⁵⁻⁵⁷ The present study 439 440 examined peak current density for variants at resting potentials of both -120 mV and at -90 441 mV.

442 When compared to a holding membrane potential of -120 mV, three variants (p.Arg1631Cys, 443 p.Arg1631His and p.Glu1783Lys) had relatively greater reduction in current density when 444 measured with a holding membrane potential of -90 mV (Table 1; Figure 5). These three variants also had altered gating properties in our study (Table 1) and previous reports.^{17,55-61} 445 446 Altered gating can impact current density by reducing channel availability. Hyperpolarizing 447 shifts in SSI can lead to channels that are not completely inactivated at physiological 448 membrane potentials (and therefore also cannot RFI) and delayed RFI can weaken 449 subsequent activations. As such, holding the resting membrane potential at -90 mV offers 450 more physiologically-relevant functional evaluations while holding membrane potentials at -451 120 mV enable the scrutiny of gating parameters that may underlie the abnormal function 452 detected at -90 mV.

It is made available under a CC-BY-NC-ND 4.0 International license .

453

454 Translational Impact of SCN5A APC Assays

455 Our validated assay was used to assess the function of SCN5A variants observed in patients 456 with suspected Brugada Syndrome or other severe arrhythmia phenotypes through 457 collaboration with their primary medical teams. After functional data were provided to each 458 clinical care site, local multi-disciplinary teams performed variant reclassification according to 459 their interpretations of the ACMG framework. Three of the four examined VUS had abnormal 460 function, and addition of this functional data resulted in all three of these variants being 461 reclassified to LP. We anticipate that our calibrated assay will be used in the future to 462 characterize additional SCN5A VUS detected in cases of suspected BrS or other 463 arrhythmias associated with SCN5A LOF.

464

465 Limitations

466 SCN5A is associated with various other cardiac phenotypes besides BrS, such as long QT syndrome, dilated cardiomyopathy, familial atrial fibrillation, and sick sinus syndrome.^{2,58,62,63} 467 468 Although our APC assay could likely be used to detect other types of $Na_v 1.5$ dysfunction, 469 this study only examined the SCN5A-BrS relationship linked to Na_V1.5 LOF variants.' To 470 enable high-throughput studies, HEK293 cell lines were employed for experiments rather 471 than induced pluripotent stem cell-derived cardiomyocytes or animal models. These models 472 may be more physiologically accurate but are more costly and at the present are lower throughput than heterologous expression experiments.⁶⁴ SCN5A function can be influenced 473 474 by several features not modelled in our study, including alternative spliced isoforms,⁶⁵ or expression of additional genes such as β-subunits^{39,65,66} or transcription factors.⁵ Despite 475 476 these limitations, the assay was still able to accurately distinguish benign from pathogenic 477 variant controls.

It is made available under a CC-BY-NC-ND 4.0 International license .

478

479 Future Directions

Additional known and yet to be discovered *SCN5A* VUS could be studied using our calibrated functional assay. Further investigations of the two variants with discordant assay results may reveal new biological mechanisms. Further implementation of multi-site replication and calibration for additional genes and disorders will broaden the impact of APC assays for precision medicine.

485

486

487 **Declarations**

488 Acknowledgements

We thank Kenneth Matreyek and Doug Fowler for the HEK293 landing pad cells, and Lorena
Harvey, Maria Calandranis, and Paige Roberson with *SCN5A* cloning assistance and cell
preparation. Figure 1 was created with BioRender.

492

493 Authors' contributions

JM, MO, JV, CN and AG contributed to the original research and analyses, drafting, and editing this paper. EB, KT, JI, AM, JS, GD, KA, BS, AS, BF, KD, VP, HC, MP and DR contributed additional genetic and clinical expertise, and helped edit the paper. All authors approved the final manuscript.

498

499 Declaration of interests

It is made available under a CC-BY-NC-ND 4.0 International license .

500 Dr. Glazer is a consultant for BioMarin, Inc. Victoria Parikh is a scientific advisory board 501 member (Lexeo Therapeutics), clinical advisor (Constantiam Biosciences) and consultant 502 (BioMarin, Inc., Viz.ai). Victoria Parikh also receives research support from BioMarin, Inc. 503 Remaining authors declare no competing interests.

504

505 Ethics approval and consent to participate

506 The University of Washington Human Subjects Division, Institutional Review Board, 507 BioMedical Committee B reviewed and granted approval for the BBI-CVD study # 14771. 508 The University of Washington's IRB FWA # is #00006878. The IRB granted expedited 509 approval for the study with consent, HIPAA authorization, parental permission and assent 510 waived, and involvement of children was approved. Stanford University School of Medicine 511 IRB gave ethical approval, and patient consent was waived based on removal of all PHI. 512 Vanderbilt University Medical Center IRB granted approval #9047. Additionally, signed 513 informed consent was received from patient. Clinical case from The Royal Melbourne 514 Hospital does not have IRB/REC as it is not an enrolled patient however, patient consent for 515 publication was received.

516

517 Availability of data and materials

All functional data are available in the accompanying Supplement and Supplementary files in .csv format. Code used to process these files is available at https://github.com/GlazerLab/ and https://github.com/VCCRI/. Individual clinical data beyond those presented in the manuscript are withheld for patient privacy. Variant classifications and functional data will be uploaded to ClinVar upon publication.

523

It is made available under a CC-BY-NC-ND 4.0 International license .

524 Funding

525 This study was funded by the National Institutes of Health (NIH): R01 HL164675 (DMR), R01 526 HL149826 (DMR), R00 HG010904 (AMG), R01 HG013025 (ABS), and R35 GM150465 527 (AMG), a New South Wales Cardiovascular Disease Senior Scientist grant (JIV), and a 528 MRFF Genomics Health Futures Mission grant MRF2016760 (JIV and CAN). MJO received 529 support from NIH grants F30HL163923 and T32GM007347. We also acknowledge support 530 from the Victor Chang Cardiac Research Institute Innovation Centre, funded by the NSW 531 Government. VUMC flow cytometry experiments were performed in the Vanderbilt Flow 532 Cytometry Shared Resource. The Vanderbilt Flow Cytometry Shared Resource is supported 533 by the Vanderbilt Ingram Cancer Center (NIH P30 CA68485) and the Vanderbilt Digestive 534 Disease Research Center (NIH DK058404). The VUMC Nanion SyncroPatch 384PE is 535 housed and managed within the Vanderbilt High-Throughput Screening Core Facility, an 536 institutionally supported core, and was funded by NIH Shared Instrumentation Grant 537 1S10OD025281. The HTS Core receives support from the Vanderbilt Institute of Chemical 538 Biology and the Vanderbilt Ingram Cancer Center (NIH P30 CA68485).

539

It is made available under a CC-BY-NC-ND 4.0 International license .

541 **References**

- Brugada, P., and Brugada, J. (1992). Right bundle branch block, persistent ST segment
 elevation and sudden cardiac death: A distinct clinical and electrocardiographic
 syndrome: A multicenter report. Journal of the American College of Cardiology 20,
 1391-1396.
- Amin, A.S., Asghari-Roodsari, A., and Tan, H.L. (2010). Cardiac sodium channelopathies.
 Pflugers Arch 460, 223-237.
- Serrone, M., Costa, S., and Delmar, M. (2022). The Genetics of Brugada Syndrome. Annu
 Rev Genomics Hum Genet.
- 4. Hosseini, S.M., Kim, R., Udupa, S., Costain, G., Jobling, R., Liston, E., Jamal, S.M.,
 Szybowska, M., Morel, C.F., Bowdin, S., et al. (2018). Reappraisal of Reported
 Genes for Sudden Arrhythmic Death. Circulation 138, 1195-1205.
- 553 5. Barc, J., Tadros, R., Glinge, C., Chiang, D.Y., Jouni, M., Simonet, F., Jurgens, S.J.,
 554 Baudic, M., Nicastro, M., Potet, F., et al. (2022). Genome-wide association analyses
 555 identify new Brugada syndrome risk loci and highlight a new mechanism of sodium
 556 channel regulation in disease susceptibility. Nature Genetics 54, 232-239.
- 6. Musunuru, K., Hershberger, R.E., Day, S.M., Klinedinst, N.J., Landstrom, A.P., Parikh,
 V.N., Prakash, S., Semsarian, C., and Sturm, A.C. (2020). Genetic Testing for
 Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart
 Association. Circulation: Genomic and Precision Medicine 13, e000067.
- 7. Wilde, A.A.M., Semsarian, C., Márquez, M.F., Sepehri Shamloo, A., Ackerman, M.J.,
 Ashley, E.A., Sternick, E.B., Barajas-Martinez, H., Behr, E.R., Bezzina, C.R., et al.
 (2022). European Heart Rhythm Association (EHRA)/Heart Rhythm Society
 (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm
 Society (LAHRS) Expert Consensus Statement on the state of genetic testing for
 cardiac diseases. EP Europace 24, euac030.
- 8. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde,
 M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the
 interpretation of sequence variants: a joint consensus recommendation of the
 American College of Medical Genetics and Genomics and the Association for
 Molecular Pathology. Genetics in Medicine 17, 405-423.
- 572 9. Landrum, M.J., Chitipiralla, S., Brown, G.R., Chen, C., Gu, B., Hart, J., Hoffman, D., Jang,
 573 W., Kaur, K., Liu, C., et al. (2019). ClinVar: improvements to accessing data. Nucleic
 574 Acids Research 48, D835-D844.
- 10. Landrum, M.J., Lee, J.M., Benson, M., Brown, G.R., Chao, C., Chitipiralla, S., Gu, B.,
 Hart, J., Hoffman, D., Jang, W., et al. (2018). ClinVar: improving access to variant
 interpretations and supporting evidence. Nucleic Acids Res 46, D1062-d1067.
- 578 11. Ackerman, M.J. (2015). Genetic purgatory and the cardiac channelopathies: Exposing 579 the variants of uncertain/unknown significance issue. Heart Rhythm 12, 2325-2331.
- Ackerman, J.P., Bartos, D.C., Kapplinger, J.D., Tester, D.J., Delisle, B.P., and
 Ackerman, M.J. (2016). The Promise and Peril of Precision Medicine: Phenotyping
 Still Matters Most. Mayo Clin Proc.
- 13. Vanoye, C.G., Desai, R.R., Fabre, K.L., Gallagher, S.L., Potet, F., DeKeyser, J.-M.,
 Macaya, D., Meiler, J., Sanders, C.R., and George, A.L. (2018). High-Throughput
 Functional Evaluation of KCNQ1 Decrypts Variants of Unknown Significance.
 Circulation: Genomic and Precision Medicine 11, e002345.
- 14. Vanoye, C.G., Desai, R.R., Ji, Z., Adusumilli, S., Jairam, N., Ghabra, N., Joshi, N., Fitch,
 E., Helbig, K.L., McKnight, D., et al. (2022). High-throughput evaluation of epilepsyassociated KCNQ2 variants reveals functional and pharmacological heterogeneity.
 JCI Insight 7.
- 591 15. Ng, C.-A., Perry, M.D., Liang, W., Smith, N.J., Foo, B., Shrier, A., Lukacs, G.L., Hill, A.P., 592 and Vandenberg, J.I. (2020). High-throughput phenotyping of heteromeric human

It is made available under a CC-BY-NC-ND 4.0 International license .

593	ether-à-go-go-related gene potassium channel variants can discriminate pathogenic
594 595	16. Jiang, C., Richardson, E., Farr, J., Hill, A.P., Ullah, R., Kroncke, B.M., Harrison, S.M.,
596	nomson, K.L., Ingles, J., Vandenberg, J.I., et al. (2022). A calibrated functional
508	OT syndrome Am I Hum Genet 109 1199-1207
590	17 Glazer A.M. Wada Y. Li B. Muhammad A. Kalash O.R. O'Neill M.I. Shields T.
600	Hall I Short I Blair MA et al (2020) High-Throughput Reclassification of
601	SCN5A Variants, Am J Hum Genet 107, 111-123.
602	18. Brnich, S.E., Abou Tavoun, A.N., Couch, F.J., Cutting, G.R., Greenblatt, M.S., Heinen,
603	C.D., Kanavy, D.M., Luo, X., McNulty, S.M., Starita, L.M., et al. (2020).
604	Recommendations for application of the functional evidence PS3/BS3 criterion using
605	the ACMG/AMP sequence variant interpretation framework. Genome Med 12, 3.
606	19. Thomson, K.L., Jiang, C., Richardson, E., Westphal, D.S., Burkard, T., Wolf, C.M., Vatta,
607	M., Harrison, S.M., Ingles, J., Bezzina, C.R., et al. (2023). Clinical interpretation of
608	KCNH2 variants using a robust PS3/BS3 functional patch clamp assay. medRxiv,
609	2023.2010.2008.23296707.
610	20. Morales, J., Pujar, S., Loveland, J.E., Astashyn, A., Bennett, R., Berry, A., Cox, E.,
611	Davidson, C., Ermolaeva, O., Farrell, C.M., et al. (2022). A joint NCBI and EMBL-EBI
612	transcript set for clinical genomics and research. Nature 604, 310-315.
613	21. Kroncke, B.M., Glazer, A.M., Smith, D.K., Blume, J.D., and Roden, D.M. (2018). SCNSA
615	(Nav I.5) Variant Functional Penurbation and Clinical Presentation: Variants of a
616	22 Karczewski K I. Francioli I. C. Tiao, G. Cummings, B.B. Alföldi I. Wang, O. Collins
617	RI Laricchia KM Ganna A Birnhaum DP et al (2020) The mutational
618	constraint spectrum quantified from variation in 141 456 humans. Nature 581 434-
619	443
620	23. Whiffin, N., Minikel, E., Walsh, R., O'Donnell-Luria, A.H., Karczewski, K., Ing, A.Y.,
621	Barton, P.J.R., Funke, B., Cook, S.A., MacArthur, D., et al. (2017). Using high-
622	resolution variant frequencies to empower clinical genome interpretation. Genet Med
623	19, 1151-1158.
624	24. Vutthikraivit, W., Rattanawong, P., Putthapiban, P., Sukhumthammarat, W.,
625	Vathesatogkit, P., Ngarmukos, T., and Thakkinstian, A. (2018). Worldwide
626	Prevalence of Brugada Syndrome: A Systematic Review and Meta-Analysis. Acta
627	Cardiol Sin 34, 267-277.
628	25. Ghosh, R., Harrison, S.M., Rehm, H.L., Plon, S.E., and Biesecker, L.G. (2018). Updated
629	recommendation for the benign stand-alone ACMG/AMP criterion. Hum Mutat 39,
630	1525-1530. 26 Tautisian S.V. Creanblatt M.S. Harrison S.M. Nusahaum B.L. Brobby S.A.
622	20. Tavligian, S.V., Greenblan, W.S., Hamson, S.W., Nussbaum, R.L., Plabhu, S.A., Boucher K.M. and Biosocker J.C. (2018) Modeling the ACMC/AMP variant
633	classification guidelines as a Bayesian classification framework. Genet Med 20
634	1054-1060
635	27. Walsh, R., Lahrouchi, N., Tadros, R., Kyndt, F., Glinge, C., Postema, P.G., Amin, A.S.,
636	Nannenberg, E.A., Ware, J.S., Whiffin, N., et al. (2021). Enhancing rare variant
637	interpretation in inherited arrhythmias through quantitative analysis of consortium
638	disease cohorts and population controls. Genetics in Medicine 23, 47-58.
639	28. Ioannidis, N.M., Rothstein, J.H., Pejaver, V., Middha, S., McDonnell, S.K., Baheti, S.,
640	Musolf, A., Li, Q., Holzinger, E., Karyadi, D., et al. (2016). REVEL: An Ensemble
641	Method for Predicting the Pathogenicity of Rare Missense Variants. The American
642	Journal of Human Genetics 99, 877-885.
643	29. Kopanos, C., Tsiolkas, V., Kouris, A., Chapple, C.E., Albarca Aguilera, M., Meyer, R.,
644	and Massouras, A. (2018). VarSome: the human genomic variant search engine.
045 646	DIVINIORMATICS 33, 1978-1980.
040 647	(2021) Heterozyaque KONH2 variant phonotyping using Elp. In UEK202 and high
1-0	

- 648 throughput automated patch clamp electrophysiology. Biol Methods Protoc 6, 649 bpab003.
- 31. O'Neill, M.J., Muhammad, A., Li, B., Wada, Y., Hall, L., Solus, J.F., Short, L., Roden,
 D.M., and Glazer, A.M. (2022). Dominant negative effects of SCN5A missense
 variants. Genetics in Medicine.
- 32. Matreyek, K.A., Stephany, J.J., Chiasson, M.A., Hasle, N., and Fowler, D.M. (2020). An
 improved platform for functional assessment of large protein libraries in mammalian
 cells. Nucleic Acids Res 48, e1.
- 33. Hermann, M., Stillhard, P., Wildner, H., Seruggia, D., Kapp, V., Sánchez-Iranzo, H.,
 Mercader, N., Montoliu, L., Zeilhofer, H.U., and Pelczar, P. (2014). Binary
 recombinase systems for high-resolution conditional mutagenesis. Nucleic Acids Res
 42, 3894-3907.
- 34. Ng, C.-A., Ullah, R., Farr, J., Hill, A.P., Kozek, K.A., Vanags, L.R., Mitchell, D.W.,
 Kroncke, B.M., and Vandenberg, J.I. (2022). A massively parallel assay accurately
 discriminates between functionally normal and abnormal variants in a hotspot domain
 of KCNH2. The American Journal of Human Genetics 109, 1208-1216.
- 35. Grant, A.O. (2009). Cardiac Ion Channels. Circulation: Arrhythmia and Electrophysiology
 2, 185-194.
- 666 36. Li, W., Yin, L., Shen, C., Hu, K., Ge, J., and Sun, A. (2018). SCN5A Variants: 667 Association With Cardiac Disorders. Front Physiol 9, 1372.
- 37. Glazer, A.M., Davogustto, G.E., Shaffer, C.M., Vanoye, C.G., Desai, R.R., Farber-Eger,
 E., Dikilitas, O., Shang, N., Pacheco, J.A., Yang, T., et al. (2022). Arrhythmia Variant
 Associations and Reclassifications in the eMERGE-III Sequencing Study. Circulation
 0, 877-891.
- 38. Marangoni, S., Di Resta, C., Rocchetti, M., Barile, L., Rizzetto, R., Summa, A., Severi,
 S., Sommariva, E., Pappone, C., Ferrari, M., et al. (2011). A Brugada syndrome
 mutation (p.S216L) and its modulation by p.H558R polymorphism: standard and
 dynamic characterization. Cardiovascular Research 91, 606-616.
- 39. Wang, D.W., Desai, R.R., Crotti, L., Arnestad, M., Insolia, R., Pedrazzini, M., Ferrandi,
 C., Vege, A., Rognum, T., Schwartz, P.J., et al. (2007). Cardiac Sodium Channel
 Dysfunction in Sudden Infant Death Syndrome. Circulation 115, 368-376.
- 40. Chen, S., Francioli, L.C., Goodrich, J.K., Collins, R.L., Kanai, M., Wang, Q., Alföldi, J.,
 Watts, N.A., Vittal, C., Gauthier, L.D., et al. (2022). A genome-wide mutational
 constraint map quantified from variation in 76,156 human genomes. bioRxiv,
 2022.2003.2020.485034.
- 41. Sommariva, E., Pappone, C., Martinelli Boneschi, F., Di Resta, C., Rosaria Carbone, M.,
 Salvi, E., Vergara, P., Sala, S., Cusi, D., Ferrari, M., et al. (2013). Genetics can
 contribute to the prognosis of Brugada syndrome: a pilot model for risk stratification.
 Eur J Hum Genet 21, 911-917.
- 42. Crotti, L., Marcou, C.A., Tester, D.J., Castelletti, S., Giudicessi, J.R., Torchio, M.,
 Medeiros-Domingo, A., Simone, S., Will, M.L., Dagradi, F., et al. (2012). Spectrum
 and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a
 cohort of unrelated patients referred for Brugada syndrome genetic testing:
 implications for genetic testing. J Am Coll Cardiol 60, 1410-1418.
- 43. Ortiz-Bonnin, B., Rinné, S., Moss, R., Streit, A.K., Scharf, M., Richter, K., Stöber, A.,
 Pfeufer, A., Seemann, G., Kääb, S., et al. (2016). Electrophysiological characterization of a large set of novel variants in the SCN5A-gene: identification of novel LQTS3 and BrS mutations. Pflügers Archiv - European Journal of Physiology 468, 1375-1387.
- 44. Shestak, A.G., Makarov, L.M., Komoliatova, V.N., Kolesnikova, I.V., Skorodumova, L.O.,
 Generozov, E.V., and Zaklyazminskaya, E.V. (2021). Coexistence of Two Rare
 Genetic Variants in Canonical and Non-canonical Exons of SCN5A: A Potential
 Source of Misinterpretation. Frontiers in Genetics 12, 722291.
- 45. Arnestad, M., Crotti, L., Rognum, T.O., Insolia, R., Pedrazzini, M., Ferrandi, C., Vege, A.,
 Wang, D.W., Rhodes, T.E., George, A.L., et al. (2007). Prevalence of Long-QT

703	Syndrome Gene Variants in Sudden Infant Death Syndrome. Circulation 115, 361-
704	46 Paludan Müller C. Chouse I. Vad O.R. Herfelt C.R. Lundegaard P. Ablberg G.
705	40. Faludari-Wuller, C., Griouse, J., Vau, O.D., Heneli, C.D., Lundeyaard, F., Alliberg, G., Schmitt, N. Svendsen, I.H. Haunsø, S. Bundaaard, H. et al. (2010). Reappraisal of
700	variants providually linked with sudden infant death syndrome: results from three
707	population based cohorte. Fur I Hum Conet 27, 1427, 1425
700	AZ Oloson MS Vuon L. Liong R. Holet A.C. Nielson N. Nielson LR. Hodlov, P.L.
709	47. Olesell, M.S., Tudil, L., Lidily, D., Tiolsi, A.G., Nielsell, N., Nielsell, J.D., Tieuley, F.L., Christianson M. Oloson S.P. Haunso S. et al. (2012) High provalance of long OT
710	sundromo associated SCN5A variante in patiente with early enset long atrial
712	fibrillation Circ Cardiovasc Genet 5 450-459
713	48 Darbar D. Kannankeril P. I. Donahue B.S. Kucera G. Stubblefield T. Haines I.I.
714	George AL and Roden D.M. (2008) Cardiac Sodium Channel (SCN5A) Variants
715	Associated with Atrial Fibrillation Circulation 117 1927-1935
716	49 Lane C.M. Giudicessi LR. Ve D. Tester D.L. Robatai R.K. Bos I.M. and
717	Ackerman M.I. (2018) Long OT syndrome type 5-Lite: Defining the clinical
718	nbenotype associated with the potentially proarrhythmic p Asp85Asp-KCNE1
719	common genetic variant Heart Rhythm 15, 1223-1230
720	50 Frustaci A Priori S.G. Pieroni M. Chimenti C. Napolitano C. Rivolta I. Sanna T.
721	Bellocci F and Russo M A (2005) Cardiac Histological Substrate in Patients With
722	Clinical Phenotype of Brugada Syndrome. Circulation 112, 3680-3687
723	51. Yamagata, K., Horie, M., Aiba, T., Ogawa, S., Aizawa, Y., Ohe, T., Yamagishi, M.,
724	Makita, N., Sakurada, H., Tanaka, T., et al. (2017). Genotype-Phenotype Correlation
725	of SCN5A Mutation for the Clinical and Electrocardiographic Characteristics of
726	Probands With Brugada Syndrome. Circulation 135, 2255-2270.
727	52. Frustaci, A., Russo, M.A., and Chimenti, C. (2009), Structural myocardial abnormalities
728	in asymptomatic family members with Brugada syndrome and SCN5A gene
729	mutation. Eur Heart J 30, 1763.
730	53. Savastano, S., Rordorf, R., Vicentini, A., Petracci, B., Taravelli, E., Castelletti, S.,
731	D'Errico, A., Torchio, M., Dossena, C., Novara, P., et al. (2014). A comprehensive
732	electrocardiographic, molecular, and echocardiographic study of Brugada syndrome:
733	validation of the 2013 diagnostic criteria. Heart Rhythm 11, 1176-1183.
734	54. Han, D., Tan, H., Sun, C., and Li, G. (2018). Dysfunctional Nav1.5 channels due to
735	SCN5A mutations. Exp Biol Med (Maywood) 243, 852-863.
736	55. Benson, D.W., Wang, D.W., Dyment, M., Knilans, T.K., Fish, F.A., Strieper, M.J.,
737	Rhodes, T.H., and George, A.L., Jr. (2003). Congenital sick sinus syndrome caused
738	by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest
739	112, 1019-1028.
740	56. Nakajima, T., Kaneko, Y., Saito, A., Ota, M., Iijima, T., and Kurabayashi, M. (2015).
741	Enhanced fast-inactivated state stability of cardiac sodium channels by a novel
742	voltage sensor SCN5A mutation, R1632C, as a cause of atypical Brugada syndrome.
743	Heart Rhythm 12, 2296-2304.
744	57. Makita, N., Behr, E., Shimizu, W., Horie, M., Sunami, A., Crotti, L., Schulze-Bahr, E.,
745	Fukuhara, S., Mochizuki, N., Makiyama, T., et al. (2008). The E1784K mutation in
746	SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J
747	Clin Invest 118, 2219-2229.
748	58. Gui, J., Wang, T., Jones, R.P., Trump, D., Zimmer, T., and Lei, M. (2010). Multiple loss-
749	of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome.
750	PLOS One 5, e10985.
751	59. Deschenes, I., Baroudi, G., Bertnet, M., Barde, I., Chaividan, T., Denjoy, I., Guicheney,
752	P., and Chanine, M. (2000). Electrophysiological characterization of SCNSA
103 751	mutations causing long QT (ET784K) and Brugada (RT512W and R1432G) syndromos Cardiovase Res 46 55 65
754	Synutomes. Odiulovaso Res 40, 00-00. 60 Abdolesved M. Barutasu A.E. Cibba K. Sanatasi S. Krahn A.D. Brahat V. and
756	Ruben P.C. (2017) Differential calcium sensitivity in Na(V) 1.5 mixed syndrome
757	mutante Physiol 595, 6165-6186
131	matania. 5 i nysioi 555, 0105-0100.

- 61. Veltmann, C., Barajas-Martinez, H., Wolpert, C., Borggrefe, M., Schimpf, R., Pfeiffer, R.,
 Cáceres, G., Burashnikov, E., Antzelevitch, C., and Hu, D. (2016). Further Insights in
 the Most Common SCN5A Mutation Causing Overlapping Phenotype of Long QT
 Syndrome, Brugada Syndrome, and Conduction Defect. Journal of the American
 Heart Association 5, e003379.
- 62. Pérez-Riera, A.R., Barbosa-Barros, R., Daminello Raimundo, R., da Costa de Rezende
 Barbosa, M.P., Esposito Sorpreso, I.C., and de Abreu, L.C. (2018). The congenital
 long QT syndrome Type 3: An update. Indian Pacing Electrophysiol J 18, 25-35.
- 63. Moreau, A., Gosselin-Badaroudine, P., Boutjdir, M., and Chahine, M. (2015). Mutations
 in the Voltage Sensors of Domains I and II of Nav1.5 that are Associated with
 Arrhythmias and Dilated Cardiomyopathy Generate Gating Pore Currents. Front
 Pharmacol 6, 301.
- 64. Sendfeld, F., Selga, E., Scornik, F.S., Pérez, G.J., Mills, N.L., and Brugada, R. (2019).
 Experimental Models of Brugada syndrome. Int J Mol Sci 20.
- 65. Tan, B.H., Valdivia, C.R., Rok, B.A., Ye, B., Ruwaldt, K.M., Tester, D.J., Ackerman, M.J.,
 and Makielski, J.C. (2005). Common human SCN5A polymorphisms have altered
 electrophysiology when expressed in Q1077 splice variants. Heart Rhythm 2, 741747.
- 66. Watanabe, H., Darbar, D., Kaiser, D.W., Jiramongkolchai, K., Chopra, S., Donahue,
 B.S., Kannankeril, P.J., and Roden, D.M. (2009). Mutations in sodium channel β1and β2-subunits associated with atrial fibrillation. Circ Arrhythm Electrophysiol 2, 268275.

780

It is made available under a CC-BY-NC-ND 4.0 International license .

782 Figures

783 Figure 1: A Calibrated SCN5A Automated Patch Clamp Assay.

(A) Overview of project design. Selection of calibration variants, independent execution of
experiments at two sites, calibration of results, and application to clinical cases. (B)
Individual site assay schematic. Minor differences in cell systems, selection drugs, and APC
conditions/analysis existed between sites and are described in the Methods.

788

789

Figure 2: Establishing an SCN5A voltage protocol and data transformation for normal distribution.

792 (A) Example traces from a single cell expressing WT SCN5A illustrating sodium 793 conductance following activation from -100 mV to +60 mV in +5 mV increments. The -30 mV 794 sweep is highlighted in orange and was used for analyses. (B) Current-voltage curves show 795 current densities at voltages -100 mV to +60 mV for WT (blue) and negative cell lines (grey). 796 Mean ± 95% confidence interval values are shown. (C-D) Violin plot of WT SCN5A current 797 density at each site (VCCRI N = 609; VUMC N = 2,118 cells). The current density of WT 798 SCN5A did not follow a normal distribution (W = 0.956 and W = 0.942 at VCCRI and VUMC, respectively; Shapiro-Wilk test). The median value and 1st and 3rd quartiles are indicated with 799 800 red lines. (E-F) Violin plots of WT SCN5A current density at each site after square root 801 transformation. The square root-transformed current densities more closely followed a 802 normal distribution (W = 0.997 and W = 0.995 at VCCRI and VUMC, respectively; Shapiro-Wilk test). The median value and 1st and 3rd guartiles are indicated with blue lines. The 803 804 resulting mean \pm SD of the square root-transformed distribution was 100 \pm 29.2 (VCCRI) and 805 100 ± 34.1 (VUMC).

806

It is made available under a CC-BY-NC-ND 4.0 International license .

807

808 Figure 3: Distinguishing pathogenic and likely pathogenic variants from benign

809 variants with Na_v1.5 peak current density measurements.

810 (A-C) Square-root transformed, normalized peak current densities at -30mV obtained by 811 VCCRI (94.1 ± 13.9; A), VUMC (94.8 ± 11.1; B) and a combined dataset (94.2 ± 10.3; C). 812 SCN5A peak I_{Na} densities (pA/pF) were measured after holding at -120 mV. The normal 813 functional range was defined as the mean ± 2 SD of the benign variant values (blue region). 814 The peak current measurements distinguished the P/LP and B variants, apart from three 815 variants (p.Ser216Leu, p.Arg1631His, and p.Arg1643Cys) discussed further in the text. (D) 816 Peak current densities from the two sites were highly correlated (p<0.0001; $R^2 = 0.86$). (E) 817 Violin plot summary of combined current densities among B and P/LP variants. Blue-filled 818 circles (•) indicated B variant controls. Red-filled circles (•) indicates P/LP variant controls. 819 Data is presented as mean \pm 95% Cl.

820

821

822 Figure 4: Analysis of channel gating parameters reveals variants that affect gating.

823 (A) SSA of p.Ala735Val compared to WT, showing a right-shift in voltage of activation. 824 Boltzmann best-fit curves are plotted. (B) Steady-state voltage of half-activation difference 825 from wildtype (SSA ΔV_{50}) for variant controls. Combined SSA ΔV_{50} = -0.37 ± 1.71. ΔV_{50} 826 represents the shift in voltage where variants are half activated, as compared to WT. (C) SSI 827 of p.Arg1631Cys compared to WT, showing a left-shift in voltage of inactivation. Boltzmann 828 best-fit curves are plotted. (D) Steady-state voltage of half-inactivation difference from 829 wildtype (SSI ΔV_{50}) for variant controls. Combined SSI $\Delta V_{50} = -0.37 \pm 1.71$. ΔV_{50} represents 830 the shift in voltage where variants are half inactivated, as compared to WT. (E) RFI of 831 p.Arg1631His compared to WT, showing a large delay in recovery post inactivation. Double 832 exponential best-fit curves are plotted. (F) RFI difference from WT (ΔT_{50}). Combined RFI

It is made available under a CC-BY-NC-ND 4.0 International license .

833	$\Delta T_{50} = 0.933 \pm 1.77$. $\Delta T50$ represents the shift in time required for channels to reach a half-
834	recovered from inactivation state as compared to WT. Many P/LP control variants did not
835	have sufficient peak current to measure the three parameters shown in this figure. (G)
836	Sample radar plots for corresponding variants with extreme shifts in gating parameters:
837	p.Ala735Val (SSA), p.Arg1631Cys (SSI) and p.Arg1631His (RFI). Radar plots for all
838	analyzed variants are presented in Figure S5. Blue-filled circles (•) indicated B variant
839	controls. Red-filled circles (•) indicates P/LP variant controls. In panels B, D, F, G, H and I,
840	the dashed line represents Z = 0, and the blue region indicates Z-scores within \pm 2. In panels
841	B, D and F, and the dotted lines indicate Z outside of \pm 4. Data is presented as mean \pm 95%
842	CI.

843

844

Figure 5: Current density measured from a physiological resting potential is a single variable that distinguishes benign from pathogenic variants.

847 (A) Protocol showing holding voltages of -120 mV -90 mV for 500 ms prior to activation of 848 channels. Sample raw traces showing current measured with holding potentials of -120 mV 849 and -90 mV for the same variant cell when depolarized to -30 mV. (B) Correlation between the different holding membrane voltages show strong correlation (R^2 =0.95), with outliers 850 851 p.Arg1631His, p.Arg1631Cys and p.Glu1783Lys. (C) Normalized current density of variant 852 controls activated from a holding voltage of -90 mV to represent the resting membrane 853 potential of human cardiomyocytes encompasses gating parameters such as SSA, SSI and 854 RFI. Mean = 91.7 \pm 14.9. Data is presented as mean \pm 95% CI. Blue-filled circles (•) 855 indicated B variant controls. Red-filled circles (•) indicates P/LP variant controls.

856

857

It is made available under a CC-BY-NC-ND 4.0 International license .

858 Figure 6: Evaluation of assay according to ClinGen SVI recommendations for

859 functional evidence

860 (A) Confusion matrix showing sensitivity and specificity of our previously deployed functional 861 assessment combining -120 mV-held peak current (Z = 2) and gating (Z = 4) properties 862 using data from both sites. (B) BS3_strong and PS3_strong may be applied for this 863 combination of parameters functional assay, following ClinGen guidelines¹⁸. (C) Confusion 864 matrix showing sensitivity and specificity for a single parameter, -90 mV-held peak current (Z 865 = 2) from the VCCRI site. The B variant p.Ser216Leu is concordantly classified in this 866 implementation of the assay. (D) BS3_strong and PS3_strong may be applied for this single parameter functional assay, following ClinGen guidelines ¹⁸. 867

868

869

870 Figure 7: Reclassification of clinically observed variants with calibrated functional

871 data.

872 (A-D) Four clinical cases of families segregating SCN5A VUS. Arrows indicate the proband. 873 Red crosses indicate variant carriers. The sexes of family members have been anonymized 874 as indicated by diamond-shaped symbols. (A) Proband with sudden cardiac arrest and 875 successful out-of-hospital defibrillation, subsequently diagnosed with Brugada Syndrome 876 and Progressive Cardiac Conduction Defect. The SCN5A VUS segregated with conduction 877 disease in the proband and the affected parent. There was a family history of cardiac 878 arrests. (B) Proband with syncope and fever-induced Type 1 Brugada pattern on ECG, with 879 a family history of recurrent syncope, seizures, and one cardiac arrest. Family members 880 were hesitant to engage in genetic testing preventing segregation analysis. (C) Pedigree of 881 family members with conduction block, cardiomyopathy, ventricular tachycardia/fibrillation 882 and aborted cardiac arrest. The SCN5A VUS segregated with a severe arrhythmia 883 phenotype in the proband and conduction block in his two young children. (D) Proband with

It is made available under a CC-BY-NC-ND 4.0 International license .

spontaneous Type 1 Brugada pattern on a screening ECG, found to have a VUS in SCN5A.
(E) ACMG/AMP classification criteria and reclassifications following incorporation of
functional data for the four clinically observed variants. Classifications were performed
independently at each clinical site by a genetic counselor, clinical geneticist, or physician
specializing in genomic medicine.

- 889
- 890
- 891

892 Table 1: Variants with outlier values for gating parameters

893

	SSA		SSI		RFI		I _{Na} Density		I _{Na} Density	
Variant							-120 mV hold		-90 mV hold	
	ΔV_{50}	Z	ΔV_{50}	Z	ΔT_{50}	Z	Norm	Z	Norm	Z
							(sqrt)		(sqrt)	
p.Ala735Val	15.14	10.54	-4.74	-1.72	9.62	4.91	50.85	-4.19	43.30	-3.18
p.Glu1224Lys	11.23	7.87	18.03	8.37	-11.90	-7.25	66.63	-2.66	54.98	-2.41
p.Arg1631Cys	7.25	5.16	-28.04	-12.04	129.60	72.74	50.28	-4.25	23.89	-4.45
p.Arg1631His	3.28	2.45	-20.90	-8.87	188.60	106.09	77.67	-1.60	39.41	-3.43
p.Glu1783Lys	8.77	6.19	-10.60	-4.31	0.24	-0.39	52.28	-4.05	26.62	-4.27

894

Severe gating changes (Z > +4 or Z < -4) were observed in five P/LP variants. p.Arg1631His,

which a had I_{Na} density value normal ranges at activation following -120 mV resting

897 potentials, had a hyperpolarized shifts in SSI and severely delayed RFI. This gating effect

898 was also visibly incorporated at activation following -90 mV resting potentials. Bolded

899 numbers indicate measurements outside the benign normal range (-4 < Z < 4 for SSA, SSI,

900 and RFI and Z < -2 for I_{Na} density).

901













